Terns Pharmaceuticals, Inc. (TERN)
NASDAQ:TERN
TERN Stock Chart & Stats
$52.62
-$0.29(-5.06%)
At close: 4:00 PM EST
$52.62
-$0.29(-5.06%)
Day’s Range― - ―
52-Week Range$2.04 - $53.19
Previous CloseN/A
Volume294.76K
Average Volume (3M)7.87M
Market Cap
$6.08B
Enterprise Value$4.22B
Total Cash (Recent Filing)$1.02B
Total Debt (Recent Filing)$919.00K
Price to Earnings (P/E)―
Beta1.24
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding115,413,390
10 Day Avg. Volume18,425,377
30 Day Avg. Volume7,868,010
Financial Highlights & Ratios
PEG Ratio4.87
Price to Book (P/B)3.74
Price to Sales (P/S)0.00
P/FCF Ratio-45.80
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-38.32
Forecast
1Y Price Target
$53.00Price Target Upside0.72% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)-1.17
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Profile And DifferentiationEarly clinical results show strong molecular response signals and generally favorable tolerability at planned doses, supporting potential for the drug to serve as both frontline and salvage therapy.
Deal Valuation And Shareholder ValueThe all-cash offer values the company above recent trading levels and provides immediate cash value to shareholders while modeling indicates meaningful commercial potential for the lead asset.
Strategic Acquisition BenefitsMerck's acquisition places the lead allosteric BCR-ABL inhibitor into a global development and commercial infrastructure that can accelerate pivotal trials and broaden market access.
Bears Say
Clinical Data UncertaintyExpanding clinical datasets showed weaker response rates as samples grew, creating uncertainty about whether the drug will demonstrate definitive efficacy and secure regulatory approval.
Deal Mechanics Deter Competing BidsA substantial termination fee and firm all-cash structure make competing bidders unlikely, which could prevent a higher offer and limit extra upside for shareholders.
Limited Upside After Announced DealAnalyst downgrades reflect that the agreed cash offer largely defines the stock price, reducing upside available from standalone company growth expectations.
Terns Pharmaceuticals News
TERN FAQ
What was Terns Pharmaceuticals, Inc.’s price range in the past 12 months?
Terns Pharmaceuticals, Inc. lowest stock price was $2.04 and its highest was $53.19 in the past 12 months.
What is Terns Pharmaceuticals, Inc.’s market cap?
Terns Pharmaceuticals, Inc.’s market cap is $6.08B.
When is Terns Pharmaceuticals, Inc.’s upcoming earnings report date?
Terns Pharmaceuticals, Inc.’s upcoming earnings report date is May 18, 2026 which is in 39 days.
How were Terns Pharmaceuticals, Inc.’s earnings last quarter?
Terns Pharmaceuticals, Inc. released its earnings results on Mar 31, 2026. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.288 by $0.038.
Is Terns Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Terns Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Terns Pharmaceuticals, Inc. pay dividends?
Terns Pharmaceuticals, Inc. does not currently pay dividends.
What is Terns Pharmaceuticals, Inc.’s EPS estimate?
Terns Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Terns Pharmaceuticals, Inc. have?
Terns Pharmaceuticals, Inc. has 115,413,390 shares outstanding.
What happened to Terns Pharmaceuticals, Inc.’s price movement after its last earnings report?
Terns Pharmaceuticals, Inc. reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.288. Following the earnings report the stock price went down -0.303%.
Which hedge fund is a major shareholder of Terns Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in TERN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Terns Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$53.00 (0.72% Upside)
$53.00 (0.72% Upside)
Blogger Sentiment
Bullish
TERN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $49.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Bearish
Bullish news 25%
Bearish news 75%
Bearish news 75%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2468.78%
12-Months-Change
Fundamentals
Return on Equity
-20.02%
Trailing 12-Months
Asset Growth
181.72%
Trailing 12-Months
Company Description
Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
TERN Stock 12 Month Forecast
Average Price Target
$53.00
▲(0.72% Upside)
Technical Analysis
AnaptysBio
―
Keros Therapeutics
―
Nurix Therapeutics
―
Olema Pharmaceuticals
―
Tyra Bioscience
―
Ownership Overview
0.92% Insiders
13.19% Mutual Funds
52.12% Other Institutional Investors
23.40% Public Companies and Individual Investors